News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GenVec Inc. Receives NIAID Biodefense Program Grant For Development Of Broadly Applicable Vaccine Technology


8/29/2006 10:03:10 AM

GenVec, Inc. (Nasdaq:GNVC) announced today that it has received a $430,000 Phase I Small Business Innovation Research award from the National Institute of Allergy and Infectious Diseases Biodefense Program to support the company's efforts to develop novel adenovector-based vaccine technology. The funding will support research to advance GenVec's adenovector technology to develop a range of vaccines based on novel serotypes of adenovirus. The new vectors produced under this grant will incorporate influenza genes to assess their improved immunogenicity.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES